![]() ![]() ![]() Standard precautions associated with injectable materials should be followed. As with all transcutaneous procedures, dermal filler implantation carries a risk of infection. The safety and effectiveness for the treatment of anatomic regions other than the labeled indications have not been established in controlled U.S. Discuss the potential risks of soft-tissue injections with your patients prior to treatment and ensure that patients are aware of signs and symptoms of potential complications. Precautions: These products should only be used by healthcare professionals who have appropriate training, experience, and knowledge of facial anatomy. Product use at specific sites in which an active inflammatory process or infection is present should be deferred until the underlying process has been controlled. Patients should receive prompt medical attention and, possibly, evaluation by an appropriate healthcare professional specialist should an intravascular injection occur. Immediately stop the injection if a patient exhibits any of the following symptoms: changes in vision, signs of a stroke, blanching of the skin, or unusual pain during or shortly after the procedure. Rare, but serious, adverse events associated with the intravascular injection of soft-tissue fillers in the face have been reported and include temporary or permanent vision impairment, blindness, cerebral ischemia or cerebral hemorrhage leading to stroke, skin necrosis, and damage to underlying facial structures. Take extra care when injecting soft-tissue fillers for example, inject the product slowly and apply the least amount of pressure necessary. Introduction of these products into the vasculature may lead to embolization, occlusion of the vessels, ischemia, or infarction. ![]() Warnings: Do not inject into blood vessels. Do not use in patients with bleeding disorders. RHA® 4 is indicated for injection in the deep dermis to superficial subcutaneous tissue for the correction of moderate to severe dynamic facial wrinkles and folds, such as nasolabial folds in adults 22 or older.Ĭontraindications: Do not use in patients who have severe allergies, marked by a history of anaphylaxis or multiple severe allergies, or in patients with a history of allergies to gram-positive bacterial proteins or local anesthetics of the amide type, such as lidocaine. RHA® 2 and RHA® 3 are indicated for injection into the mid-to-deep dermis for the correction of moderate to severe dynamic facial wrinkles and folds, such as nasolabial folds in adults 22 or older. RHA Redensity™ is indicated for injection into the dermis and superficial dermis of the face, for the correction of moderate to severe dynamic perioral rhytids in adults 22 or older. Indications: The RHA® Collection of resilient hyaluronic acid (HA) fillers includes RHA Redensity™, RHA® 2, RHA® 3 and RHA® 4. ![]()
0 Comments
Leave a Reply. |